Royal Bank of Canada’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-27,938
| Closed | -$106K | – | 7137 |
|
|
2020
Q1 | $106K | Buy |
27,938
+24,718
| +768% | +$106K | ﹤0.01% | 4748 |
|
|
2019
Q4 | $15K | Buy |
3,220
+2,276
| +241% | +$12K | ﹤0.01% | 6003 |
|
|
2019
Q3 | $4K | Buy |
944
+500
| +113% | +$2.49K | ﹤0.01% | 6153 |
|
|
2019
Q2 | $3K | Sell |
444
-80
| -15% | -$386 | ﹤0.01% | 6530 |
|
|
2019
Q1 | $2K | Sell |
524
-355
| -40% | -$1.61K | ﹤0.01% | 6587 |
|
|
2018
Q4 | $3K | Sell |
879
-3,651
| -81% | -$18.6K | ﹤0.01% | 6397 |
|
|
2018
Q3 | $30K | Buy |
4,530
+914
| +25% | +$7.02K | ﹤0.01% | 5487 |
|
|
2018
Q2 | $30K | Buy |
3,616
+542
| +18% | +$4.14K | ﹤0.01% | 5379 |
|
|
2018
Q1 | $24K | Buy |
3,074
+795
| +35% | +$5.29K | ﹤0.01% | 5392 |
|
|
2017
Q4 | $14K | Sell |
2,279
-4,059
| -64% | -$24.7K | ﹤0.01% | 5752 |
|
|
2017
Q3 | $47K | Buy |
6,338
+5,503
| +659% | +$35K | ﹤0.01% | 5455 |
|
|
2017
Q2 | $6K | Sell |
835
-451
| -35% | -$3.33K | ﹤0.01% | 6005 |
|
|
2017
Q1 | $13K | Sell |
1,286
-2,741
| -68% | -$27.4K | ﹤0.01% | 5851 |
|
|
2016
Q4 | $35K | Buy |
+4,027
| New | +$29.8K | ﹤0.01% | 5469 |
|
|
2016
Q3 | – | Sell |
-438
| Closed | -$1K | – | 6676 |
|
|
2016
Q2 | $1K | Sell |
438
-629
| -59% | -$3.04K | ﹤0.01% | 6297 |
|
|
2016
Q1 | $5K | Sell |
1,067
-9,901
| -90% | -$44.1K | ﹤0.01% | 5939 |
|
|
2015
Q4 | $67K | Sell |
10,968
-27,719
| -72% | -$182K | ﹤0.01% | 5168 |
|
|
2015
Q3 | $221K | Buy |
38,687
+38,652
| +110,434% | +$297K | ﹤0.01% | 4241 |
|
|
2015
Q2 | $0 | Sell |
35
-265
| -88% | -$1.6K | ﹤0.01% | 6796 |
|
|
2015
Q1 | $2K | Sell |
300
-450
| -60% | -$2.83K | ﹤0.01% | 5925 |
|
|
2014
Q4 | $6K | Buy |
750
+450
| +150% | +$2.69K | ﹤0.01% | 5768 |
|
|
2014
Q3 | $2K | Sell |
300
-55
| -15% | -$274 | ﹤0.01% | 5814 |
|
|
2014
Q2 | $1K | Buy |
355
+55
| +18% | +$210 | ﹤0.01% | 5842 |
|
|
2014
Q1 | $1K | Hold |
300
| – | – | ﹤0.01% | 5821 |
|
|
2013
Q4 | $2K | Sell |
300
-827
| -73% | -$3.64K | ﹤0.01% | 5780 |
|
|
2013
Q3 | $6K | Buy |
1,127
+827
| +276% | +$4.49K | ﹤0.01% | 5597 |
|
|
2013
Q2 | $1K | Buy |
+300
| New | +$1.35K | ﹤0.01% | 5754 |
|
Other funds holding PGNX
Royal Bank of Canada's PGNX Position: Q2 2020 in Review
Royal Bank of Canada sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 27,938 shares — an estimated $106K sold.
Royal Bank of Canada first reported a position in PGNX in Q2 2013 and held it in 27 quarters. The position peaked at $221K in Q3 2015. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Royal Bank of Canada reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Royal Bank of Canada sold 27,938 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $106K.
- Royal Bank of Canada first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 27 quarters.
- Royal Bank of Canada's Progenics Pharmaceuticals Inc position peaked at $221K in Q3 2015.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Royal Bank of Canada's 13F filing for Q2 2020, filed 14 Aug 2020.